Literature DB >> 9302273

Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease.

D J Lehmann1, C Johnston, A D Smith.   

Abstract

The allelic frequency of the gene for the K variant of butyrylcholinesterase (BCHE-K) was 0.17 in 74 subjects with late-onset (age > 65 years) histopathologically diagnosed Alzheimer's disease (AD), which was higher than the frequencies in 104 elderly control subjects (0.09), in 14 early-onset cases of confirmed AD (0.07) and in 29 confirmed cases of other dementia (0.10). The association of BCHE-K with late-onset AD was limited to carriers of the epsilon 4 allele of the apolipoprotein E gene (APOE), among whom the presence of BCHE-K gave an odds ratio of confirmed late-onset AD of 6.9 (95% C.I. 1.65-29) in subjects > 65 years and of 12.8 (1.9-86) in subjects > 75 years. In APOE epsilon 4 carriers over 75 years, only 1/22 controls, compared with 10/24 confirmed late-onset AD cases, had BCHE-K. We suggest that BCHE-K, or a nearby gene on chromosome 3, acts in synergy with APOE epsilon 4 as a susceptibility gene for late-onset AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302273     DOI: 10.1093/hmg/6.11.1933

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  29 in total

Review 1.  Genetic risk factors in Alzheimer's disease.

Authors:  L Tilley; K Morgan; N Kalsheker
Journal:  Mol Pathol       Date:  1998-12

2.  GAB2 gene does not modify the risk of Alzheimer's disease in Spanish APOE 4 carriers.

Authors:  R Ramirez-Lorca; M Boada; M E Saez; I Hernandez; A Mauleon; M Rosende-Roca; P Martinez-Lage; M Gutierrez; L M Real; J Lopez-Arrieta; J Gayan; C Antunez; A Gonzalez-Perez; L Tarraga; A Ruiz
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

3.  The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease.

Authors:  P G Kehoe; H Williams; P Holmans; G Wilcock; N J Cairns; J Neal; M J Owen
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

Review 4.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Gohar Mushtaq; Nigel H Greig; Jalaluddin A Khan; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

Review 5.  Emerging links between type 2 diabetes and Alzheimer's disease.

Authors:  Gumpeny R Sridhar; Gumpeny Lakshmi; Gumpeny Nagamani
Journal:  World J Diabetes       Date:  2015-06-10

Review 6.  Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?

Authors:  E Giacobini
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 7.  Interleukin-1 and the immunogenetics of Alzheimer disease.

Authors:  R E Mrak; W S Griffin
Journal:  J Neuropathol Exp Neurol       Date:  2000-06       Impact factor: 3.685

8.  Butyrylcholinesterase is complexed with transferrin in chicken serum.

Authors:  E Weitnauer; C Ebert; F Hucho; A Robitzki; C Weise; P G Layer
Journal:  J Protein Chem       Date:  1999-02

9.  BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Authors:  Alessandra Bizzarro; V Guglielmi; R Lomastro; A Valenza; A Lauria; C Marra; M C Silveri; F D Tiziano; C Brahe; C Masullo
Journal:  J Neural Transm (Vienna)       Date:  2010-03       Impact factor: 3.575

10.  Association study of candidate gene polymorphisms with amnestic mild cognitive impairment in a Chinese population.

Authors:  Xiaoyan Liu; Chunxian Yue; Zhi Xu; Hao Shu; Mengjia Pu; Hui Yu; Yongmei Shi; Liying Zhuang; Xiaohui Xu; Zhijun Zhang
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.